jokerpokertable|重药控股枸橼酸托法替布片获得药品注册证书

Heavy Pharmaceutical Holdings announced on the evening of May 5JokerpokertableChongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of the company, recently received the relevant "Drug Registration Certificate" approved and issued by the State Drug Administration.Jokerpokertable: 5mg) "after examination, it meets the relevant requirements of drug registration and approves the registration.

Data show that Topatib Citrate is a Janus kinase (JAK) inhibitor developed by Pfizer for the treatment of inflammatory-related immune diseases. It was first listed in the United States in 2012 and entered China in 2017 under the trade name Shangjie / XELJANZ. Its indications include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and so on.

Up to now, domestic manufacturers who have approved the listing of Topatix Citrate tablets include Pfizer, the original drug research factory, Zhengda Tianqing Pharmaceutical Co., Ltd., Qilu Pharmaceutical, Zhejiang Huahai Pharmaceutical Co., Ltd., and other enterprises. In November 2022, heavy Pharmaceutical shares submitted an application for registration and listing with the State Drug Administration, which was accepted.

Heavy Pharmaceutical Holdings said its subsidiaries carry out drug research and development and production in the form of drug marketing licensees (MAH) and strictly control the quality and safety of drugs throughout their life cycle. After obtaining the above drug registration documents, it can be produced and sold in China, further enrich the company's preparation variety, form a reasonable complementarity with the company's traditional drug distribution business, and improve the company's market competitiveness. At the same time, according to the relevant national policies, the approved production of Topatibu Citrate tablets according to the four categories of chemicals can be regarded as passing the consistency evaluation, which will help to expand the market sales of the company's products and have a positive impact on the future business performance.

It is understood that prior to this, the company has successively obtained the "Drug Registration Certificate" of olmesartan axetil tablets (registration classification: chemicals 4; specifications: 20mg) and Preba capsules (registration classification: chemicals 4; specifications: 75mg, 150mg). In the next step, the company will continue to adhere to the principle of "clinical value, market value and investment value", develop the pharmaceutical industry chain in depth, and continue to invest in high-end generic drugs with high technology and high equipment barriers and innovative drugs with clinical demands. actively develop characteristic traditional Chinese medicine products, pay attention to the development trend of biological products, and promote the high-quality development of the company. (Wang Yi)